Gouty Arthritis (Gout) Pipeline Therapeutics Development Review H2 2015

Press Release   •   Jan 13, 2016 09:14 EST

Gouty Arthritis (Gout) - Pipeline Review, H2 2015

Gouty Arthritis (Gout) - Pipeline Review, H2 2015 market research report is the latest addition to and its collection of therapeutics business intelligence reports aimed to help take better decisions.

This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Gouty Arthritis” addition with 38 market data tables and 15 figures, spread across 117 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

AstraZeneca Plc, Celtaxsys, Inc., CymaBay Therapeutics, Inc., Delenex Therapeutics AG, Immune Response BioPharma, Inc., IOmet Pharma, JW Pharmaceutical Corporation, LG Life Science LTD., Monosol Rx, LLC, Nimbus Therapeutics, LLC, Omni Bio Pharmaceutical Inc., Opsona Therapeutics Limited, PLx Pharma Inc., Polaris Pharmaceuticals, Inc., Selecta Biosciences, Inc., Takeda Pharmaceutical Company Limited, Teijin Limited, TWi Pharmaceuticals, Inc. and Wellstat Therapeutics Corporation

Drugs Profile Discussed in this Research:

acebilustat, arhalofenate, AXIBU-03, colchicine, diacerein, DLX-2323, DLX-2681, FcAAT-2, FcAAT-3, febuxostat, febuxostat XR, IR-888, LC-350189, lesinurad sodium, Moniclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders, ND-2110, ND-2158, ND-346, pegadricase, PL-4100, RDEA-3170, Recombinant Enzyme for Gout and Tumor Lysis Syndrome, Recombinant Protein to Replace Alpha-1 Antitrypsin Cardiovascular, Metabolic Disorders, Immunology, Gastrointestinal Disease, RLBN-1001, RLBN-2020 Series, RLBN-3010 Series, Small Molecule Inflammasome Modulator Programme, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecules to Inhibit GLUT9 for Gout, URC-102, uriSHELS, WT-2107, XEN-102 and XEN-104

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Arthritis Therapeutics Market.

Since the invention of user friendly gadgets, humans have learned to become lazy and make the gizmos responsible for both good and bad. Even the irritable pollution is made accountable for interfering in normal features of a humanoid body. But blaming others is just not the solution of any problem. It is now that Arthritis therapeutics enters actively in to the scenario.

Fast growing drug market with ample choices in front of the therapists makes this pharmaceutical industry reach its desired height of success. In fact with more number of people suffering from rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), surely accelerates their growth in this sector. Globally the pharmaceutical companies are now ready to make more investments as higher returns are for sure. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries